Glioblastoma (GBM) is a hypervascular and aggressive primary malignant tumor of the central 38 nervous system. Recent investigations showed that traditional therapies along with antiangiogenic 39 therapies failed due to the development of post-therapy resistant and recurrent GBM. Our 40 investigations show that there are changes in the cellular and metabolic compositions in the tumor 41 microenvironment (TME). It can be said that tumor cell-directed therapies are ineffective and we 42 need to rethink how to treat GBM. 43 We hypothesize that the composition of TME-associated cells will be different based on the 44 therapy and therapeutic agents, and TME-targeting therapy will be better to decrease recurrence 45 and improve survival. Therefore, the purpose of this study is to determine the changes in the TME 46 in respect of T-cell population, M1 and M2 macrophage polarization status, and MDSC population 47 following different treatments in a syngeneic model of GBM. In addition to these parameters, 48 tumor growth and survival were also studied following different treatments.
treatments, orthotopic GBM models using syngeneic GL261 cells in wild type and CSF1R 165 conditional knockout C57BL/6 mice were prepared according to our published methods (8, 10, 11, 166 44). In short, luciferase positive GL261 cells were grown in standard growth media (RPMI-1640 167 plus 10% FBS) and collected in serum-free media on the day of implantation. After preparation 168 and drilling a hole at 2.25 mm (athymic nude mice) to the right and 2 mm posterior to the bregma, 169 taking care not to penetrate the dura, a 10 µL Hamilton syringe with a 26G-needle containing 170 tumor cells (10,000) in a volume of 3 µl was lowered to a depth of 4 mm and then raised to a depth 171 of 3 mm. During and after the injection, a careful note was made for any reflux from the injection 172 site. After completing the injection, we waited 2-3 minutes before withdrawing the needle 1 mm 173 at a time in a stepwise manner. The surgical hole was sealed with bone wax. Finally, the skull was 174 swabbed with betadine before suturing the skin (45-47). There were at least three animals in each Treatments: All treatments were started on day 8 following tumor implantation and continued for 180 two weeks. The following treatment groups were used to determine the TME associated T-cells, 181 different macrophages, MDSCs present by flow cytometry; 1) vehicle, 2) HET0016 complexed 182 with HPßCD at 10mg/kg/day for 5 days/week, intravenous (IV), 3) GW2580, 160mg/kg/day 183 3day/week, oral, 4) temozolomide (TMZ) 50mg/kg/day, 3days/week, oral, 5) Vatalanib 184 50mg/kg/day, 5 days/week, oral, 6) Navarixin, 10mg/kg/day, 5 days/week, intraperitoneal (IP), 7) 185 anti-PD-1 antibody, 200µg/dose, 2 doses/week, IP, 8) image guided radiation therapy, 186 10Gy/dose/week for two weeks, 9) combined HET0016 plus GW2580, 10) combined HET0016 187 plus GW2580 plus anti-PD-1 antibody.
188

Making of a conditional knockout mouse model of bone marrow-derived CSF1R+ myeloid
189 cells: Heterozygous CSF1R flox/wt/MX1-Cre+ male was mated with a heterozygous CSF1R 190 flox/wt/MX1-Cre+ female to achieve 25% of the progeny with homozygous CSF1Rflox/flox/MX1-191 Cre+ (knockout) genotype in bone marrow cells. Other progeny was wild-type CSF1Rwt/wt/MX-1-192 Cre+ (25%) and heterozygous CSF1Rflox/wt/MX-1-Cre+ (50%) genotypes. After repeated cross-193 breeding, we have generated a colony of CSF1Rflox/flox/Cre+ (knockout). These animals are healthy 194 and are being used for breeding. Analysis of myeloid cells in the peripheral blood before and after 195 injection of polyinosinic-polycytidylic acid (poly-IC) showed bone marrow-specific depletion of 196 CSF1R+ cells (Figure 1) . These animals (male and female) were used to generate GL261 derived 197 syngeneic GBM after depletion of bone marrow-derived myeloid cells and then treated with 198 HET0016 or anti PD-1 antibody alone or in combination or with CXCR2 antagonist SB225002 199 (10mg/kg/day 5 days/week, IP) for two weeks.
200
Determination of bone marrow-derived cells in the TME: Following euthanasia, animals were 201 perfused with ice-cold PBS and the right brain containing GBM was collected, passed through 40- For BLI (optical imaging) data, the general framework of analyses included two-way ANOVA 223 followed by either Tukey's or Sidak's multiple comparisons. We analyzed the survival of the animals 224 following different treatments. Log-rank test (Mantel-Cox) was applied to determine the significance 225 of differences among the groups. A P value of 0.05 was considered significant.
227
Results: 228 In this study, we successfully developed CSF1R conditional knockout mouse. These conditional 229 knock out mice showed homozygous CSF1R flox/flox /MX1-Cre+ (knockout) genotype ( Figure 1A) . 230 Compared to wild type mice, conditional knockout mice showed a significant dose-dependent 231 decrease in CD45+CSF1R+ cells following two weeks of treatments with poly-IC. There was 232 almost 80% decrease of CSF1R+ cells in the peripheral blood ( Figure 1B) . Wild type mice treated 233 with poly-IC did not show any significant difference in CD45+CSF1R+ cells ( Figure 1C ). Both 234 wild type (control) and knockout mice (after two weeks' of treatments with poly-IC) received 235 intracranial implantation of syngeneic GL261 glioblastoma. On day 8 of tumor implantation, 236 groups of animals received either vehicle or SB225002 for two weeks. All animals underwent 237 optical imaging pre and post-treatment. Photon intensities were determined to measure tumor 238 growth. Wild type control animals showed significantly increased tumor growth ( Figure 1D ) 239 which is indicated by a 10-fold increase in the photon intensity ( Figure 1E) . On the other hand, 240 both wild type (control) treated with SB225002 and knockout mice showed significantly decreased 241 tumor growth at week 3, indicating the involvement of CSF1R+ cells in the TME. It is also known 242 that the CXCR2 antagonist can inhibit the function of myeloid cells by blocking the interaction of 243 CXCR2 and IL-8 (48-50). Tumor-associated CD45+CD11b+CD86+ and CD45+CD11b+CD206+ 244 cells were determined following treatment with SB225002 in wild type animals. Both cell types 245 were significantly decreased following the treatments (Figure 1F) . T-cells and MDSC populations 246 showed no significant difference between the treated and untreated wild type animals.
247
Both wild type and CSF1R knockout mice received different treatments that target tumor cells or 248 tumor-associated cells. All treatments were for two weeks and the treatment was started on day 8 249 7 of orthotopic tumor implantation. On day 22 following last optical imaging, animals were 250 euthanized and the tumors were collected for flow cytometry to determine the population of T-251 cells (CD4, CD8), CD11b+ cells, macrophages (M1 and M2), and MDSCs (Ly6C and Ly6G). To 252 our surprise, CD4, CD8, CD11b, and Ly6G positive cells significantly increased in tumors treated 253 with TMZ (Figure 2) . On the other hand, different cellular populations were significantly 254 decreased in post-radiation tumors. All other treatments that targeted tumor-associated myeloid 255 cells or checkpoint showed increased accumulation of CD4 and CD8 cells in the tumors but 256 myeloid cell populations including MDSCs, CD11b+ cells, and macrophages showed insignificant 257 changes in the TME compared to that of control and Vatalanib treated tumors (Figure 3) . 258 All animals that were followed for survival and euthanized on day 22 to determine the TME 259 associated cells also underwent optical imaging before treatment and at one and two weeks after animals. It should be noted that the animals that received TME-associated cell-directed therapy 271 showed significantly lower tumor growth 2 weeks following treatments. The animals that receive 272 antiangiogenic (Vatalanib) and tumor cell-targeted (TMZ) therapy exhibited rebound tumor 273 growth at 2 weeks of treatments. 274 We instituted different treatments targeting both tumor cells and the tumor microenvironment 275 including arachidonic acid metabolisms and anti-depressant (selective serotonin reuptake inhibitor 276 (SSRI), fluoxetine) drugs alone or in combination with TMZ. We also used a very high dose of 277 HET0016 (50mg/kg/day). Usual dose of HET0016 is 10mg/kg/day. All treatments significantly 278 increased the survival of animals bearing syngeneic GL261 GBM (Figure 5A) . The most 279 significantly increased survival was observed in animals' groups that were treated with TMZ, 280 HET0016, TMZ+HET0016, and with a HET analog. Although Navarixin (IL-8CXCR2 axis 281 blocker) increased the survival of the animals, the addition of TMZ did not improve survival 282 (Figure 5B) . are non-effective treatment strategies (10, 45, 60-65). Investigations from our lab indicated that 294 most of the instituted therapies mobilized bone-marrow cells to the sites of GBM and orchestrated 295 therapy resistance (10, 11). Our results showed that antiangiogenic therapies initiate alternate 296 vascularization pathways and eventually increased neovascularization in therapy-resistant GBM 297 (7, 45, 66). We found that angiogenic and vasculogenic myeloid cells accumulated at GBM sites 298 following therapies(11, 65). Furthermore, we reported the process of vascular mimicry in which 299 GBM cells transdifferentiate into glioma stem cells that can then form functional blood vessels (7, 300 67). All of these results support our conclusion that the possible changes occurring in the TME 301 following standard or investigational treatments in GBM have not been properly studied. This 302 includes both changes in TME associated cells as well as the changes that occur in the metabolic 303 cascade of TME associated cells. In this pilot study, we aimed to investigate these changes. To 304 accomplish this, we used standard therapies (radiation and TMZ) as well as agents that targeted 305 TME associated cells (CSF1R inhibitor GW2580 to target myeloid cells, IL-8-CXCR2 antagonists 306 Navarixin and SB225002 to target stem cells causing vascular mimicry, anti-PD1 antibody 307 targeting immune suppressive molecules) and different metabolic pathways (HET0016 and its 308 analog to target CYP4A-20-HETE axis of arachidonic acid metabolisms, fluoxetine to target 309 serotonin reuptake). Following therapies, we determined the changes in the composition of TME-310 associated cells and the survival benefit of the therapeutic agents alone or in combination with 311 TMZ.
312
Our results clearly demonstrated the importance of TME associated CSF1R positive cells. Animals 313 treated with GW2580 and conditional knockout animals (CSF1R knockout) showed a decreased 314 number of myeloid cells in the TME, whereas TMZ therapy increased the population of myeloid produce an immunosuppressive microenvironment that promotes tumor growth. Following 319 chemotherapy, macrophage differentiation is altered to promote the production of cancer-320 supporting M2 macrophages in the TME (71). Chemotherapy has also been shown to promote 321 macrophage aggregation, thus facilitating cathepsin protease B-and S-mediated therapy resistance 322 (72). Some chemotherapeutic agents activate MDSCs to produce IL-1β. This leads to the secretion 323 of IL-17 by CD4 + T-cells (73). Additionally, MDSCs have been shown to partake in the epithelial-324 mesenchymal transition, increase the production of multiple matrix metalloproteinases, and merge 325 tumor cells (71-73). Therefore, the addition of myeloid cell blockage could mitigate these 326 mechanisms of resistance. However, it is to note that, previous investigations also indicated the 327 development of resistance following long-term therapy using CSF1R inhibitors (74, 75). This 328 indicates the importance of sequential or intermittent therapy targeting GBM TME associated cells 329 following or in between standard therapies for GBM.
330
To our surprise, we noticed a decreased accumulation of T-cells as well as different myeloid cell 331 populations in the TME following radiation therapies. This decreased accumulation of T-cells may 332 be due to the disruption of intact blood vessels that act as a delivery system of T-cells to the tumor 333 site. This disruption is likely caused by radiation therapy-induced necrosis in tumors leading to 334 tumor cell death. Therefore, most tumor recurrence in post-radiation GBM occurs from the 335 periphery of the irradiated areas where a few cells may have survived the radiation injury. Our 336 previous studies showed that the addition of HET0016 (blocker of CYP4A-20-HETE axis of 337 arachidonic acid metabolisms) improved the survival of animals bearing patient-derived xenograft 338 (PDX) GBM following 30Gy of radiotherapy (8). HET0016 is known to inhibit tumor and 339 9 endothelial cell (EC) proliferation, EC migration, and prevent neovascularization including 340 vascular mimicry (44, 67, 76). Although we have not tested agents that prevent the repair of DNA 341 damage, the addition of PARP inhibitor may also help prevent the recurrence of GBM following 342 radiotherapy (77, 78). However, in contrast to HET0016, PARP inhibitor has a very narrow 343 therapeutic window and causes severe toxicity (77). Therefore, adding an inhibitor of arachidonic 344 acid metabolic pathways may be useful in preventing the recurrence of post-radiation GBM. 345 Previously, we have reported the effectiveness of HET0016 in controlling GBM and breast cancer 346 (8, 32). However, we had not yet reported TME-associated cells present following the treatment 347 of HET0016. In this study, HET0016 treatment exhibited a similar phenomenon to that of myeloid 348 cell-targeted therapies. It showed an increased T-cell population in the TME compared to that of 349 vehicle and Vatalanib treated GBM. There was also a tendency to decrease immunosuppressive 350 myeloid cell populations in the TME. Additionally, treatments using HET0016 and its analog 351 showed significantly improved survival which corroborates with our previous reports (8). Our HET0016 mediated therapies and its mechanisms are discussed in our previous reports (8).
356
Therefore, we propose that the use of an inhibitor of the cytochrome P450 γ-hydroxylase pathway 357 of arachidonic acid metabolisms may be used as an agent to target post-therapy GBM to prevent 358 recurrence.
359
In conclusion: current GBM therapies should be revisited to add agents to prevent the 360 accumulation of bone marrow-derived cells in the TME or to prevent the effect of immune-361 suppressive myeloid cells in causing alternative neovascularization, the revival of glioma stem 362 cells, and recurrence. Instead of concurrent therapy, a sequential strategy would be best to target 363 TME associated cells. week, and 2 weeks after treatment. There was no significant difference between all treatment 670 groups compared to that of vehicle-treated animals after 1 week of treatment except the Vatanallib 671 treated group that showed significant tumor growth. Following 2 weeks of treatment, tumor 672 growths were substantially increased in the vehicle, Vatalanib, and TMZ treated animals. All other 673 groups showed increased tumor growth but were significantly slower than the above-mentioned 674 groups. increased survival, the addition of TMZ with it did not improve the outcome.
